leisure time -WSS

leisure time

author：comprehensive 2025-10-02 00:41:08 - browse：33

Warning sign illustration made of 0s and 1s. -- first opinion coverage from sTAT — Adobe

Big businesses poised to profit from the advance of artificial intelligence in health care are pushing back against newly proposed federal rules meant to increase oversight and fairness of AI tools used to help make decisions about patient care.

The opposition, which includes Google and Amazon as well as large health care providers, insurers, and medical software vendors, is focused on an attempt to put tighter guardrails around the use of AI by the Office of the National Coordinator for Health Information Technology.

The agency wants to require developers of electronic health records and other health software to provide users with details about the training and testing of predictive models that draw data from their systems, or are hosted within them. It also wants developers to assess and publicly disclose potential risks and create a way for clinicians and other users to report problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Will Ozempic

focus

WSS

Fetal surgery at risk from Dobbs and new abortion restrictions

Hospital price transparency does save money, advocate argues

Pediatric cancer treatments threatened by a new FDA policy

What don’t we know about an Alzheimer’s drug side effect?

Senate committee scrutinizes Medicare Advantage brokers

Flagship Pioneering launches a new biotech in two countries

explore

leisure time

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

The EPA's new lead rule: How one expert crunched the numbers

Drug repurposing or repositioning? The language matters

How to pay for weight loss drugs and save Medicare

Virginia high school admissions case could be legal follow

Lawmakers consider Medicare pay reforms for doctors

Wildfire smoke exposes gaps in outdoor worker protections

Flagship Pioneering launches a new biotech in two countries

Medical leaders decry Supreme Court decision on affirmative action

Flagship Pioneering launches a new biotech in two countries

hotspot

FDA warns J&J's Abiomed: We will regulate your software

Fetal surgery at risk from Dobbs and new abortion restrictions

CEOs share strategies for surviving biotech slump

The EPA's new lead rule: How one expert crunched the numbers

FDA warns J&J's Abiomed: We will regulate your software

Takeda, Janssen join wearable maker to measure scratching

explore

focus

entertainment

focus